| Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. | |
| | |
MedLine Citation:
|
PMID: 20539226 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Current options for glycemic control are less than optimal in terms of efficacy and to reduce complications in the diabetic population. Selective inhibition of SGLT2 in the proximal tubule increases urinary glucose excretion thereby reducing plasma glucose levels, which may present a novel therapeutic approach. RECENT FINDINGS: SGLT2 inhibitors enhance glucose excretion and improve glycemic control in patients with type 2 diabetes in the absence of clinically relevant hypoglycemia or sustained changes in volume status or glomerular filtration rate. This is associated with lowering of body weight and may reduce systolic blood pressure. The increased glucosuria appears to increase the risk of genital infections but may not increase the risk of urinary tract infections. SUMMARY: The ability of SGLT2 inhibitors to reduce plasma glucose without inducing increased insulin secretion, clinically relevant hypoglycemia, or weight gain constitutes a major advance. The ability to increase glucose excretion provides a powerful means to treat caloric excess conditions. Important questions remain to be resolved and more clinical research is needed on the long-term effects of SGLT2 inhibition. Potential extrarenal effects need to be explored in order to determine the safety of these compounds. It also remains to be determined whether these drugs lower the toxicity of glucose directly on renal cells, independent of hyperglycemia, which may slow or prevent the progressive nature of diabetic nephropathy. |
| | |
Authors:
|
Volker Vallon; Kumar Sharma |
Related Documents
:
|
2583876 - Differential effect of type i and type ii diabetes mellitus on serum ampicillin levels. 18342016 - Increased urinary 1,n6-ethenodeoxyadenosine and 3,n4-ethenodeoxycytidine excretion in t... 17672206 - Significant positive correlation of plasma bpde-albumin adducts to urinary 1-hydroxypyr... 17728966 - Association of glomerular and tubular dysfunction with glycaemic control, lipid, lipopr... 16598106 - Impact of diabetes on five-year outcomes after vein graft interventions performed prior... 15930956 - Role of macrophage tissue infiltration in metabolic diseases. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review |
Journal Detail:
|
Title: Current opinion in nephrology and hypertension Volume: 19 ISSN: 1535-3842 ISO Abbreviation: Curr. Opin. Nephrol. Hypertens. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-12 Completed Date: 2010-11-22 Revised Date: 2010-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 9303753 Medline TA: Curr Opin Nephrol Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 425-31 Citation Subset: IM |
Affiliation:
|
Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego/Veterans Affairs San Diego Healthcare System, San Diego, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorption Diabetes Mellitus / drug therapy*, etiology, metabolism Diabetes Mellitus, Type 2 / drug therapy Diabetic Nephropathies / etiology Glucose / metabolism Glucosides / therapeutic use Humans Kidney / metabolism Sodium-Glucose Transporter 2 / antagonists & inhibitors*, genetics, physiology |
| Grant Support | |
ID/Acronym/Agency:
|
DK28602/DK/NIDDK NIH HHS; DK56248/DK/NIDDK NIH HHS; P30DK079337/DK/NIDDK NIH HHS; R01 DK 053867/DK/NIDDK NIH HHS; R01 DK028602-37/DK/NIDDK NIH HHS; U01 DK 060995/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; 0/Glucosides; 0/SLC5A2 protein, human; 0/Sodium-Glucose Transporter 2; 0/sergliflozin; 50-99-7/Glucose |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Molecular physiology of the Rh ammonia transport proteins.
Next Document: Fixed-dose combination and chronic kidney disease progression: which is the best?